Victor Vergara Abreu, MD
Endocrinology · Humacao, PRNPI 1558312389
Payments from drug & device makers
Across 81 payments — averaging $2600.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$197K
- Merck$6K
- Johnson & Johnson$5K
- Sanofi-aventis U.S. LLC$426
- Boehringer Ingelheim$381
- Novo Nordisk$362
- plus $642 from 8 others
Across 3 payments — averaging $1019.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Speaking & faculty fees$10,68082%
- Travel & lodging$410%
- Food & beverage$2,22817%
- Education$851%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $197,293 |
| Merck | 12 | $6,414 |
| Johnson & Johnson | 8 | $5,158 |
| Sanofi-aventis U.S. LLC | 22 | $426 |
| Boehringer Ingelheim | 17 | $381 |
| Novo Nordisk | 4 | $362 |
| Eli Lilly | 2 | $290 |
| Lilly USA, LLC | 2 | $90 |
| Medtronic | 3 | $85 |
| Mannkind Corporation | 1 | $59 |
| Abbott | 3 | $58 |
| AstraZeneca | 2 | $30 |
| Amgen | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 526 | $570,422 |
| OzempicSemaglutide | 348 | $353,806 |
| FarxigaDapagliflozin Propanediol | 365 | $280,096 |
| JardianceEmpagliflozin | 334 | $258,880 |
| SynthroidLevothyroxine Sodium | 2,487 | $163,828 |
| JanuviaSitagliptin Phosphate | 158 | $121,193 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 201 | $118,686 |
| JanumetSitagliptin Phos/Metformin Hcl | 94 | $73,123 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 67 | $72,851 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 95 | $64,953 |
| TradjentaLinagliptin | 84 | $63,008 |
| MounjaroTirzepatide | 50 | $53,944 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $43,732 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $39,688 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 56 | $38,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humalog Mix 75-25 | $90 | $657,655796 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr, Jentadueto Xr | $381 | $505,548677 claims |
| Novo NordiskOzempic | $362 | $353,806348 claims |
| MerckJanuvia, Janumet Xr, Janumet | $6,414 | $313,002453 claims |
| AstraZenecaFarxiga | $30 | $280,096365 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $426 | $96,339268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Humacao
- Lydia Rodriguez OrtizSan Juan$2K
- Gloria RodriguezSan Juan$655
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.